CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue
Operating expenses:
General and administrative (including stock-based compensation)	859,011	397,743	2,356,047	1,506,839
Depreciation	461	252	1,185	832
Research and development (including stock-based compensation)	24,242	29,411	67,833	145,624
Total operating expenses	883,714	427,406	2,425,065	1,653,295
Loss from operations	(883,714)	(427,406)	(2,425,065)	(1,653,295)
Other (income) expense:
Interest income	(1,342)	(1,338)	(4,652)	(4,101)
Interest expense	(24,488)	51,361	86,892	281,906
Gain on sale of domain		(902,490)		(902,490)
Gain on debt extinguishment				(10,234,501)
Total other expense	(25,830)	(852,467)	82,240	(10,859,186)
Net income (loss)	(857,884)	425,061	(2,507,305)	9,205,891
Net loss attributable to the noncontrolling interest		549		1,544
Net income (loss) applicable to Bion's common stockholders	$ (857,884)	$ 425,610	$ (2,507,305)	$ 9,207,435
Net income (loss) applicable to Bion's common stockholders per basic and diluted common share	$ (0.02)	$ 0.01	$ (0.06)	$ 0.22
Weighted-average number of common shares outstanding:
Basic and diluted	45,456,417	43,029,511	44,165,309	41,602,390